Developer Mission Street has bolstered its advisory team with the appointments of two life science investors to the board.
Peter Finan, a partner at venture capital firm Epidarex Capital, and Jonathan Hepple, founder of Rosetta Capital, a secondary venture firm focused on life sciences, will join Tim Funnell, an existing member of Mission Street’s board.
Finan has more than 30 years’ experience in drug discovery and has been involved in the creation of 25 new life sciences companies across the UK and US. Prior to Epidarex, he was global head of respiratory diseases at Novartis, where he was also site head for the Novartis research facility in the UK.
Finan also currently sits on the BioIndustry Association board and executive committee, advising on strategy for engagement with key stakeholders, including UK government. Hepple is a strategic adviser to Oxford Science Enterprises and is on the board of Mission Therapeutics, Carrick Therapeutics and Nucleome Therapeutics.
The appointments come as Mission Street continues to deliver and scale its portfolio. The advisory board is expected to bring expertise from the perspective of customers, investors, company founders and operations professionals.
The firm plans to grow the advisory board to include investors and founders with experience from early stage start-ups up to senior-level operational experience at mature pharmaceutical companies.
Artem Korolev, founder and chief executive of Mission Street, said: “As a specialist investor seeking to create ecosystems, it is critical to understand what our customers’ challenges and opportunities are, establishing what they actually want, and where they want it.”
To send feedback, e-mail evelina.grecenko@eg.co.uk or tweet @Gre_Eve or @EGPropertyNews
